Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase NA 4Phase 2/3 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Dermatologic 1

Conditions

Uterine Cervical Dysplasia 2

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Imiquimod × Gynecologic × Clear all
NCT02130323 2017-06-27

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

United States Naval Medical Center, San Diego

Phase 2/3 Completed
22 enrolled
Gynecologic

Uterine Cervical Dysplasia

NCT00941252 2011-01-24

ITIC

Medical University of Vienna

Phase 2/3 Completed
60 enrolled
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡